Tivdak / Tisotumab vedotin
Pharmacokinetics only · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Actemra / Tocilizumab
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tasmar / Tolcapone
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Detrol / Tolterodine tartrate
Dose or interval change · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Samsca / Tolvaptan
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Topamax / Topiramate
Dose or interval change · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Trokendi XR / Topiramate
Dose or interval change · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Remodulin / Treprostinil
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tyvaso DPI / Treprostinil
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Anoro Ellipta / Umeclidinium bromide and vilanterol trifenatate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Diovan / Valsartan
No adjustment within stated limits · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Sabril / Vigabatrin
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Erivedge / Vismodegib
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lupkynis / Voclosporin
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Zontivity / Vorapaxar
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Vytorin / Ezetimibe and simvastatin
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Relenza / Zanamivir
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
RETROVIR / Retrovir IV / Zidovudine
Dose or interval change · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
Ambien / Zolpidem tartrate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details